Mercado de degradación de proteínas dirigida, tamaño, tendencia \" crecimiento 2025-2035

---

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & Forecast Parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Targeted Protein Degradation Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Is the rising demand for novel cancer therapies targeting previously “undruggable” proteins driving market growth?

3.2.2. How are increasing R&D investments from pharmaceutical and biotech companies boosting targeted degradation technologies?

3.2.3. Are advancements in PROTACs and molecular glue platforms enhancing therapeutic efficacy and shaping market trends?

3.3. Key industry pitfalls & challenges

3.3.1. Does limited understanding of long-term safety and off-target effects hinder clinical application of protein degraders?

3.3.2. How do high development costs and technical complexities in designing selective degraders pose challenges to market expansion?

3.3.3. Is regulatory uncertainty around the novel mechanism of action affecting drug approval timelines for targeted degraders?

3.4. Market Opportunities

3.4.1. Can targeted degraders expand into autoimmune and neurodegenerative disease markets?

3.4.2. Are pharma-biotech collaborations unlocking new innovation in degradation-based therapies?

3.4.3. Will the development of oral degraders improve patient compliance and expand the market reach?

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Targeted Protein Degradation Market, Technology Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Technology, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Proteolysis-Targeting Chimeras

4.2.1. Market Size and Forecast, 2025-2035 (USD Million)

4.3. Molecular Glues

4.3.1. Market Size and Forecast, 2025-2035 (USD Million)

4.4. Lysosome Targeting Chimeras

4.4.1. Market Size and Forecast, 2025-2035 (USD Million)

4.5. Others

4.5.1. Market Size and Forecast, 2025-2035 (USD Million)

5. Targeted Protein Degradation Market, Application Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Application, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Oncology

5.2.1. Market Size and Forecast, 2025-2035 (USD Million)

5.3. Neurodegenerative Diseases

5.3.1. Market Size and Forecast, 2025-2035 (USD Million)

5.4. Autoimmune Disorders

5.4.1. Market Size and Forecast, 2025-2035 (USD Million)

5.5. Infectious Diseases

5.5.1. Market Size and Forecast, 2025-2035 (USD Million)

5.6. Others

5.6.1. Market Size and Forecast, 2025-2035 (USD Million)

6. Targeted Protein Degradation Market, Drug Type Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Drug Type, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Small Molecule-based Degraders

6.2.1. Market Size and Forecast, 2025-2035 (USD Million)

6.3. Biologic-based Degraders

6.3.1. Market Size and Forecast, 2025-2035 (USD Million)

7. Targeted Protein Degradation Market, Route of Administration Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By Route of Administration, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Oral

7.2.1. Market Size and Forecast, 2025-2035 (USD Million)

7.3. Injectable

7.3.1. Market Size and Forecast, 2025-2035 (USD Million)

8. Targeted Protein Degradation Market, End-user Segment Analysis

8.1. Overview

8.1.1. Market Revenue Share, By End-user, 2025 & 2035

8.1.2. Key Market Trends, Growth Factors, & Opportunities

8.2. Pharmaceutical & Biotechnology Companies

8.2.1. Market Size and Forecast, 2025-2035 (USD Million)

8.3. Academic & Research Institutes

8.3.1. Market Size and Forecast, 2025-2035 (USD Million)

8.4. Contract Research Organizations

8.4.1. Market Size and Forecast, 2025-2035 (USD Million)

8.5. Others

8.5.1. Market Size and Forecast, 2025-2035 (USD Million)

9. Targeted Protein Degradation Market, Region Segment Analysis

9.1. Overview

9.1.1. Global Market Revenue Share, By Region, 2025 & 2035

9.1.2. Global Market Revenue, By Region, 2025-2035 (USD Million)

9.2. North America

9.2.1. North America Market Revenue, By Country, 2025-2035 (USD Million)

9.2.2. North America Market Revenue, By Technology, 2025-2035

9.2.3. North America Market Revenue, By Application, 2025-2035

9.2.4. North America Market Revenue, By Drug Type, 2025-2035

9.2.5. North America Market Revenue, By Route of Administration, 2025-2035

9.2.6. North America Market Revenue, By End-user, 2025-2035

9.2.7. The U.S.

9.2.7.1. U.S. Market Revenue, By Technology, 2025-2035

9.2.7.2. U.S. Market Revenue, By Application, 2025-2035

9.2.7.3. U.S. Market Revenue, By Drug Type, 2025-2035

9.2.7.4. U.S. Market Revenue, By Route of Administration, 2025-2035

9.2.7.5. U.S. Market Revenue, By End-user, 2025-2035

9.2.8. Canada

9.2.8.1. Canada Market Revenue, By Technology, 2025-2035

9.2.8.2. Canada Market Revenue, By Application, 2025-2035

9.2.8.3. Canada Market Revenue, By Drug Type, 2025-2035

9.2.8.4. Canada Market Revenue, By Route of Administration, 2025-2035

9.2.8.5. Canada Market Revenue, By End-user, 2025-2035

9.3. Europe

9.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Million)

9.3.2. Europe Market Revenue, By Technology, 2025-2035

9.3.3. Europe Market Revenue, By Application, 2025-2035

9.3.4. Europe Market Revenue, By Drug Type, 2025-2035

9.3.5. Europe Market Revenue, By Route of Administration, 2025-2035

9.3.6. Europe Market Revenue, By End-user, 2025-2035

9.3.7. Germany

9.3.7.1. Germany Market Revenue, By Technology, 2025-2035

9.3.7.2. Germany Market Revenue, By Application, 2025-2035

9.3.7.3. Germany Market Revenue, By Drug Type, 2025-2035

9.3.7.4. Germany Market Revenue, By Route of Administration, 2025-2035

9.3.7.5. Germany Market Revenue, By End-user, 2025-2035

9.3.8. France

9.3.8.1. France Market Revenue, By Technology, 2025-2035

9.3.8.2. France Market Revenue, By Application, 2025-2035

9.3.8.3. France Market Revenue, By Drug Type, 2025-2035

9.3.8.4. France Market Revenue, By Route of Administration, 2025-2035

9.3.8.5. France Market Revenue, By End-user, 2025-2035

9.3.9. U.K.

9.3.9.1. U.K. Market Revenue, By Technology, 2025-2035

9.3.9.2. U.K. Market Revenue, By Application, 2025-2035

9.3.9.3. U.K. Market Revenue, By Drug Type, 2025-2035

9.3.9.4. U.K. Market Revenue, By Route of Administration, 2025-2035

9.3.9.5. U.K. Market Revenue, By End-user, 2025-2035

9.3.10. Italy

9.3.10.1. Italy Market Revenue, By Technology, 2025-2035

9.3.10.2. Italy Market Revenue, By Application, 2025-2035

9.3.10.3. Italy Market Revenue, By Drug Type, 2025-2035

9.3.10.4. Italy Market Revenue, By Route of Administration, 2025-2035

9.3.10.5. Italy Market Revenue, By End-user, 2025-2035

9.3.11. Spain

9.3.11.1. Spain Market Revenue, By Technology, 2025-2035

9.3.11.2. Spain Market Revenue, By Application, 2025-2035

9.3.11.3. Spain Market Revenue, By Drug Type, 2025-2035

9.3.11.4. Spain Market Revenue, By Route of Administration, 2025-2035

9.3.11.5. Spain Market Revenue, By End-user, 2025-2035

9.3.12. Rest of Europe

9.3.12.1. Rest of Europe Market Revenue, By Technology, 2025-2035

9.3.12.2. Rest of Europe Market Revenue, By Application, 2025-2035

9.3.12.3. Rest of Europe Market Revenue, By Drug Type, 2025-2035

9.3.12.4. Rest of Europe Market Revenue, By Route of Administration, 2025-2035

9.3.12.5. Rest of Europe Market Revenue, By End-user, 2025-2035

9.4. Asia Pacific

9.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Million)

9.4.2. Asia Pacific Market Revenue, By Technology, 2025-2035

9.4.3. Asia Pacific Market Revenue, By Application, 2025-2035

9.4.4. Asia Pacific Market Revenue, By Drug Type, 2025-2035

9.4.5. Asia Pacific Market Revenue, By Route of Administration, 2025-2035

9.4.6. Asia Pacific Market Revenue, By End-user, 2025-2035

9.4.7. China

9.4.7.1. China Market Revenue, By Technology, 2025-2035

9.4.7.2. China Market Revenue, By Application, 2025-2035

9.4.7.3. China Market Revenue, By Drug Type, 2025-2035

9.4.7.4. China Market Revenue, By Route of Administration, 2025-2035

9.4.7.5. China Market Revenue, By End-user, 2025-2035

9.4.8. Japan

9.4.8.1. Japan Market Revenue, By Technology, 2025-2035

9.4.8.2. Japan Market Revenue, By Application, 2025-2035

9.4.8.3. Japan Market Revenue, By Drug Type, 2025-2035

9.4.8.4. Japan Market Revenue, By Route of Administration, 2025-2035

9.4.8.5. Japan Market Revenue, By End-user, 2025-2035

9.4.9. India

9.4.9.1. India Market Revenue, By Technology, 2025-2035

9.4.9.2. India Market Revenue, By Application, 2025-2035

9.4.9.3. India Market Revenue, By Drug Type, 2025-2035

9.4.9.4. India Market Revenue, By Route of Administration, 2025-2035

9.4.9.5. India Market Revenue, By End-user, 2025-2035

9.4.10. Australia

9.4.10.1. Australia Market Revenue, By Technology, 2025-2035

9.4.10.2. Australia Market Revenue, By Application, 2025-2035

9.4.10.3. Australia Market Revenue, By Drug Type, 2025-2035

9.4.10.4. Australia Market Revenue, By Route of Administration, 2025-2035

9.4.10.5. Australia Market Revenue, By End-user, 2025-2035

9.4.11. South Korea

9.4.11.1. South Korea Market Revenue, By Technology, 2025-2035

9.4.11.2. South Korea Market Revenue, By Application, 2025-2035

9.4.11.3. South Korea Market Revenue, By Drug Type, 2025-2035

9.4.11.4. South Korea Market Revenue, By Route of Administration, 2025-2035

9.4.11.5. South Korea Market Revenue, By End-user, 2025-2035

9.4.12. Singapore

9.4.12.1. Singapore Market Revenue, By Technology, 2025-2035

9.4.12.2. Singapore Market Revenue, By Application, 2025-2035

9.4.12.3. Singapore Market Revenue, By Drug Type, 2025-2035

9.4.12.4. Singapore Market Revenue, By Route of Administration, 2025-2035

9.4.12.5. Singapore Market Revenue, By End-user, 2025-2035

9.4.13. Rest of Asia Pacific

9.4.13.1. Rest of Asia Pacific Market Revenue, By Technology, 2025-2035

9.4.13.2. Rest of Asia Pacific Market Revenue, By Application, 2025-2035

9.4.13.3. Rest of Asia Pacific Market Revenue, By Drug Type, 2025-2035

9.4.13.4. Rest of Asia Pacific Market Revenue, By Route of Administration, 2025-2035

9.4.13.5. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035

9.5. Latin America

9.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Million)

9.5.2. Latin America Market Revenue, By Technology, 2025-2035

9.5.3. Latin America Market Revenue, By Application, 2025-2035

9.5.4. Latin America Market Revenue, By Drug Type, 2025-2035

9.5.5. Latin America Market Revenue, By Route of Administration, 2025-2035

9.5.6. Latin America Market Revenue, By End-user, 2025-2035

9.5.7. Brazil

9.5.7.1. Brazil Market Revenue, By Technology, 2025-2035

9.5.7.2. Brazil Market Revenue, By Application, 2025-2035

9.5.7.3. Brazil Market Revenue, By Drug Type, 2025-2035

9.5.7.4. Brazil Market Revenue, By Route of Administration, 2025-2035

9.5.7.5. Brazil Market Revenue, By End-user, 2025-2035

9.5.8. Argentina

9.5.8.1. Argentina Market Revenue, By Technology, 2025-2035

9.5.8.2. Argentina Market Revenue, By Application, 2025-2035

9.5.8.3. Argentina Market Revenue, By Drug Type, 2025-2035

9.5.8.4. Argentina Market Revenue, By Route of Administration, 2025-2035

9.5.8.5. Argentina Market Revenue, By End-user, 2025-2035

9.5.9. Mexico

9.5.9.1. Mexico Market Revenue, By Technology, 2025-2035

9.5.9.2. Mexico Market Revenue, By Application, 2025-2035

9.5.9.3. Mexico Market Revenue, By Drug Type, 2025-2035

9.5.9.4. Mexico Market Revenue, By Route of Administration, 2025-2035

9.5.9.5. Mexico Market Revenue, By End-user, 2025-2035

9.5.10. Rest of Latin America

9.5.10.1. Rest of Latin America Market Revenue, By Technology, 2025-2035

9.5.10.2. Rest of Latin America Revenue, By Application, 2025-2035

9.5.10.3. Rest of Latin America Market Revenue, By Drug Type, 2025-2035

9.5.10.4. Rest of Latin America Market Revenue, By Route of Administration, 2025-2035

9.5.10.5. Rest of Latin America Market Revenue, By End-user, 2025-2035

9.6. MEA

9.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Million)

9.6.2. MEA Market Revenue, By Technology, 2025-2035

9.6.3. MEA Market Revenue, By Application, 2025-2035

9.6.4. MEA Market Revenue, By Drug Type, 2025-2035

9.6.5. MEA Market Revenue, By Route of Administration, 2025-2035

9.6.6. MEA Market Revenue, By End-user, 2025-2035

9.6.7. GCC Countries

9.6.7.1. GCC Countries Market Revenue, By Technology, 2025-2035

9.6.7.2. GCC Countries Market Revenue, By Application, 2025-2035

9.6.7.3. GCC Countries Market Revenue, By Drug Type, 2025-2035

9.6.7.4. GCC Countries Market Revenue, By Route of Administration, 2025-2035

9.6.7.5. GCC Countries Market Revenue, By End-user, 2025-2035

9.6.8. South Africa

9.6.8.1. South Africa Market Revenue, By Technology, 2025-2035

9.6.8.2. South Africa Market Revenue, By Application, 2025-2035

9.6.8.3. South Africa Market Revenue, By Drug Type, 2025-2035

9.6.8.4. South Africa Market Revenue, By Route of Administration, 2025-2035

9.6.8.5. South Africa Market Revenue, By End-user, 2025-2035

9.6.9. Rest of Middle-East & Africa

9.6.9.1. Rest of Middle-East & Africa Market Revenue, By Technology, 2025-2035

9.6.9.2. Rest of Middle-East & Africa Market Revenue, By Application, 2025-2035

9.6.9.3. Rest of Middle-East & Africa Market Revenue, By Drug Type, 2025-2035

9.6.9.4. Rest of Middle-East & Africa Market Revenue, By Route of Administration, 2025-2035

9.6.9.5. Rest of Middle-East & Africa Market Revenue, By End-user, 2025-2035

10. Company Profile

10.1. Arvinas, Inc.

10.1.1. Business Overview

10.1.2. Financial Performance

10.1.3. Product/Service Offerings

10.1.4. Strategies & recent developments

10.1.5. SWOT Analysis

10.2. C4 Therapeutics

10.2.1. Business Overview

10.2.2. Financial Performance

10.2.3. Product/Service Offerings

10.2.4. Strategies & recent developments

10.2.5. SWOT Analysis

10.3. Nurix Therapeutics

10.3.1. Business Overview

10.3.2. Financial Performance

10.3.3. Product/Service Offerings

10.3.4. Strategies & recent developments

10.3.5. SWOT Analysis

10.4. Kymera Therapeutics

10.4.1. Business Overview

10.4.2. Financial Performance

10.4.3. Product/Service Offerings

10.4.4. Strategies & recent developments

10.4.5. SWOT Analysis

10.5. Monte Rosa Therapeutics

10.5.1. Business Overview

10.5.2. Financial Performance

10.5.3. Product/Service Offerings

10.5.4. Strategies & recent developments

10.5.5. SWOT Analysis

10.6. Vividion Therapeutics

10.6.1. Business Overview

10.6.2. Financial Performance

10.6.3. Product/Service Offerings

10.6.4. Strategies & recent developments

10.6.5. SWOT Analysis

10.7. Bristol Myers Squibb

10.7.1. Business Overview

10.7.2. Financial Performance

10.7.3. Product/Service Offerings

10.7.4. Strategies & recent developments

10.7.5. SWOT Analysis

10.8. Roche Holding AG

10.8.1. Business Overview

10.8.2. Financial Performance

10.8.3. Product/Service Offerings

10.8.4. Strategies & recent developments

10.8.5. SWOT Analysis

10.9. Pfizer Inc.

10.9.1. Business Overview

10.9.2. Financial Performance

10.9.3. Product/Service Offerings

10.9.4. Strategies & recent developments

10.9.5. SWOT Analysis

10.10. Amgen Inc.

10.10.1. Business Overview

10.10.2. Financial Performance

10.10.3. Product/Service Offerings

10.10.4. Strategies & recent developments

10.10.5. SWOT Analysis

10.11. Merck & Co., Inc.

10.11.1. Business Overview

10.11.2. Financial Performance

10.11.3. Product/Service Offerings

10.11.4. Strategies & recent developments

10.11.5. SWOT Analysis

10.12. Novartis AG

10.12.1. Business Overview

10.12.2. Financial Performance

10.12.3. Product/Service Offerings

10.12.4. Strategies & recent developments

10.12.5. SWOT Analysis

10.13. Foghorn Therapeutics

10.13.1. Business Overview

10.13.2. Financial Performance

10.13.3. Product/Service Offerings

10.13.4. Strategies & recent developments

10.13.5. SWOT Analysis

10.14. Captor Therapeutics

10.14.1. Business Overview

10.14.2. Financial Performance

10.14.3. Product/Service Offerings

10.14.4. Strategies & recent developments

10.14.5. SWOT Analysis

10.15. BioTheryX

10.15.1. Business Overview

10.15.2. Financial Performance

10.15.3. Product/Service Offerings

10.15.4. Strategies & recent developments

10.15.5. SWOT Analysis